Brain Health

Insilico Medicine reports positive Phase IIa results for ISM001-055 for the treatment of idiopathic pulmonary fibrosis (IPF) designed using generative AI

Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results from its Phase IIa clinical trial evaluating ISM001-055, a first-in-class small molecule targeting TNIK (Traf2- and Nck-interacting kinase). ISM001-055 was designed using a unique AI platform to…